Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Avidity Biosciences (RNA) EBIT (2019 - 2025)

Historic EBIT for Avidity Biosciences (RNA) over the last 7 years, with Q3 2025 value amounting to -$188.8 million.

  • Avidity Biosciences' EBIT fell 9239.61% to -$188.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$612.5 million, marking a year-over-year decrease of 8862.76%. This contributed to the annual value of -$378.9 million for FY2024, which is 6084.01% down from last year.
  • According to the latest figures from Q3 2025, Avidity Biosciences' EBIT is -$188.8 million, which was down 9239.61% from -$171.1 million recorded in Q2 2025.
  • Over the past 5 years, Avidity Biosciences' EBIT peaked at -$23.9 million during Q1 2021, and registered a low of -$188.8 million during Q3 2025.
  • Its 5-year average for EBIT is -$73.8 million, with a median of -$57.6 million in 2023.
  • Its EBIT has fluctuated over the past 5 years, first crashed by 28791.87% in 2021, then crashed by 1368.28% in 2023.
  • Over the past 5 years, Avidity Biosciences' EBIT (Quarter) stood at -$38.5 million in 2021, then tumbled by 38.08% to -$53.2 million in 2022, then fell by 25.4% to -$66.7 million in 2023, then crashed by 81.28% to -$121.0 million in 2024, then crashed by 56.05% to -$188.8 million in 2025.
  • Its EBIT was -$188.8 million in Q3 2025, compared to -$171.1 million in Q2 2025 and -$131.5 million in Q1 2025.